Healthcare

Regentis Announces Four-Year Exclusive GelrinC Distribution Agreement in Israel

Regentis Biomaterials has appointed AMI Medical Technologies as the exclusive Israeli distributor of GelrinC under a four-year agreement that includes minimum purchase requirements.

Published:
Reading Time
2 min

Regentis Biomaterials Ltd. has announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for GelrinC, its hydrogel implant for repairing damaged knee cartilage, in Israel. The agreement includes minimum purchase requirements, while Regentis expects initial revenue contributions to begin during 2027.

#AMI appointed exclusive Israeli distributor

Under the agreement, AMI will handle the distribution of GelrinC in Israel. Regentis said the distributor will draw on established relationships with orthopaedic surgeons, hospitals and clinics across the country.

AMI, founded in 1986, distributes advanced medical technologies in Israel and represents medical device manufacturers including Stryker. Its activities include orthopaedic products, sports medicine, knee and joint replacement, surgical robotics, clinical training, technical support and implementation services.

#Regulatory status and reimbursement plans

GelrinC has approval from Israel’s Ministry of Health through an AMAR medical device registration certificate. The Israeli approval covers the same indication approved in Europe and being pursued in the United States.

Regentis and AMI plan to work with Israel’s leading Health Maintenance Organizations to establish reimbursement coverage and support use of GelrinC by orthopaedic surgeons treating focal cartilage defects.

Until that coverage is in place, the announcement says many Israeli patients may be able to access GelrinC through their private health insurance. The transaction carries further terms that are not set out in this article.

#GelrinC product and US clinical programme

Regentis describes GelrinC as a cell-free, off-the-shelf hydrogel implant designed to treat painful injuries affecting focal articular knee cartilage. The company says the implant is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage through a controlled process.

GelrinC is also being evaluated in a pivotal US Food and Drug Administration study. Regentis said the study had completed over 50% enrollment and described the US programme as a pivotal Phase III clinical programme.

#Forward-looking considerations

Regentis’ expectations for the timing and amount of revenue from Israel, the extent of AMI’s purchases, the establishment of reimbursement pathways and the progress of the US clinical programme are forward-looking matters subject to uncertainties and assumptions.

The company identified risks including clinical results, regulatory approval, market acceptance, reimbursement, competing therapies, product demand and future financing needs. It also noted that GelrinC’s potential benefits and performance, as well as the timing and results of its development programme, may not develop as anticipated.

#Key Takeaways

  • Regentis announced a four-year exclusive distribution agreement with AMI Medical Technologies for GelrinC in Israel.
  • The agreement includes minimum purchase requirements, with initial revenue contributions expected by Regentis during 2027.
  • GelrinC has Israeli Ministry of Health approval through an AMAR medical device registration certificate.
  • Regentis and AMI will seek reimbursement coverage through Israel’s leading Health Maintenance Organizations.
  • GelrinC is being assessed in a pivotal US FDA study that had completed over 50% enrollment.

Original source: Read original article

Frequently Asked Questions